Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Depreciation and Depletion (2022 - 2025)

Candel Therapeutics recorded quarterly Depreciation and Depletion of $100000.0 in Q4 2025, down 50.0% quarter-over-quarter from $200000.0 in Q3 2025, and down 66.67% year-over-year from $300000.0 in Q4 2024.

Candel Therapeutics' Depreciation and Depletion history runs 4 years deep, the most recent figure standing at $100000.0 for Q4 2025.

  • In Q4 2025, Depreciation and Depletion fell 66.67% year-over-year to $100000.0; the TTM figure through Dec 2025 stood at $745000.0 (down 25.5% YoY), while the FY2025 annual figure was $800000.0, down 20.0% from the prior year.
  • Depreciation and Depletion came in at $100000.0 for Q4 2025 at Candel Therapeutics, down from $200000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $300000.0 in Q4 2023 to a low of $100000.0 in Q4 2025.
  • A 4-year average of $222153.8 and a median of $200000.0 in 2023 frame the typical range for Depreciation and Depletion.
  • Across the five-year window, Depreciation and Depletion surged 50.0% in 2024 and plunged 66.67% in 2025, its largest moves.
  • Candel Therapeutics' Depreciation and Depletion stood at $243000.0 in 2022, then advanced by 23.46% to $300000.0 in 2023, then changed by 0.0% to $300000.0 in 2024, then sank by 66.67% to $100000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods registered $100000.0, $200000.0, and $200000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Candel Therapeutics 449.62 Mn 449.62 Mn - 100,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 100,000.00
Dec 31, 2025 100,000.00
Sep 30, 2025 200,000.00
Sep 30, 2025 200,000.00
Jun 30, 2025 200,000.00
Jun 30, 2025 200,000.00
Mar 31, 2025 245,000.00
Mar 31, 2025 245,000.00
Dec 31, 2024 300,000.00
Dec 31, 2024 300,000.00
Sep 30, 2024 200,000.00
Sep 30, 2024 200,000.00
Jun 30, 2024 200,000.00
Jun 30, 2024 200,000.00
Mar 31, 2024 300,000.00
Mar 31, 2024 300,000.00
Dec 31, 2023 300,000.00
Dec 31, 2023 300,000.00
Sep 30, 2023 200,000.00
Sep 30, 2023 200,000.00
Jun 30, 2023 200,000.00
Jun 30, 2023 200,000.00
Mar 31, 2023 200,000.00
Mar 31, 2023 200,000.00
Dec 31, 2022 243,000.00
Dec 31, 2022 243,000.00